During the DSUR reporting period, macitentan was generally well tolerated No significant new information relative to previously identified safety concerns was received during the DSUR reporting period.The safety and tolerability profile of macitentan (10 mg and 75 mg) was consistent with that observed in other trials in the approved indication (PAH) and study populations such as pediatric PAH, CTEPH, HFpEF/left ventricular diastolic dysfunction, and Fontan-palliated patients.